Physician profile
Farhad Melamed
NPI 1134150444
$11,947.81
in general payments reported to CMS, 2019-2025
62 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,007 · 2020: $1,140 · 2021: $1,740 · 2022: $1,154 · 2023: $1,490 · 2024: $1,984 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,905.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,903.50 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,263.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,125.84 | 2019-2025 | |
| Daiichi Sankyo INC. | $987.05 | 2019-2025 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $608.06 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.26 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $465.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.29 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $448.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $358.99 | 2019-2024 | Pifeltro, Delstrigo, Dificid |
| Janssen Pharmaceuticals, INC | $252.34 | 2020-2024 | Xarelto |
| Janssen Biotech, INC. | $249.20 | 2021-2025 | Tremfya, Stelara |
| Glaxosmithkline, LLC. | $247.57 | 2019-2024 | Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $215.66 | 2024 | Dupixent |
| Pfizer INC. | $159.86 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Melamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.